- Home
- ANNX vs QTRX Comparison
ANNX vs QTRX Comparison
Compare ANNX & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- QTRX
- Stock Information
- Founded
- ANNX 2011
- QTRX 2007
- Country
- ANNX United States
- QTRX United States
- Employees
- ANNX N/A
- QTRX N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- QTRX Biotechnology: Laboratory Analytical Instruments
- Sector
- ANNX Health Care
- QTRX Industrials
- Exchange
- ANNX Nasdaq
- QTRX Nasdaq
- Market Cap
- ANNX 253.8M
- QTRX 261.7M
- IPO Year
- ANNX 2020
- QTRX 2017
- Fundamental
- Price
- ANNX $2.64
- QTRX $5.32
- Analyst Decision
- ANNX Strong Buy
- QTRX Hold
- Analyst Count
- ANNX 5
- QTRX 4
- Target Price
- ANNX $13.00
- QTRX $11.75
- AVG Volume (30 Days)
- ANNX 1.6M
- QTRX 678.6K
- Earning Date
- ANNX 11-13-2025
- QTRX 11-11-2025
- Dividend Yield
- ANNX N/A
- QTRX N/A
- EPS Growth
- ANNX N/A
- QTRX N/A
- EPS
- ANNX N/A
- QTRX N/A
- Revenue
- ANNX N/A
- QTRX $125,784,000.00
- Revenue This Year
- ANNX N/A
- QTRX N/A
- Revenue Next Year
- ANNX N/A
- QTRX $37.89
- P/E Ratio
- ANNX N/A
- QTRX N/A
- Revenue Growth
- ANNX N/A
- QTRX N/A
- 52 Week Low
- ANNX $1.29
- QTRX $4.05
- 52 Week High
- ANNX $7.85
- QTRX $15.86
- Technical
- Relative Strength Index (RSI)
- ANNX 62.43
- QTRX 54.05
- Support Level
- ANNX $2.32
- QTRX N/A
- Resistance Level
- ANNX $2.70
- QTRX $4.92
- Average True Range (ATR)
- ANNX 0.16
- QTRX 0.24
- MACD
- ANNX 0.06
- QTRX -0.06
- Stochastic Oscillator
- ANNX 87.57
- QTRX 99.63
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.